FierceBiotechOriginal article
{"a":[{"_":"Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues","$":{"href":"/biotech/sanofis-new-ceo-looking-deeply-late-stage-pipeline-clinical-clearout-continues","hreflang":"en"}}]}
negativeitepekimabNegative
AI Analysis
Summary
Sanofi's new CEO Belén Garijo is evaluating the company's late-stage pipeline as part of a clinical strategy shift, including the discontinuation of the Regeneron-partnered IL-33 candidate itepekimab amid ongoing clinical setbacks.
Outcome Details
Late-stage IL-33 candidate itepekimab being discontinued; clinical clearout continuing
Importance:6/10
Sentiment:
-0.70
pipeline reductionclinical discontinuationpartnership impactnew leadership strategy
Read the original article
Published by FierceBiotech on July 30, 2026 5:01 AM